Comparison of availability and accessibility of oral oncology products between Medicare, commercial US, and UK National Health Service patient populations

Olubiyi Aworunse, MBBS MPH Candidate1, Lincy S. Lal, PharmD, PhD2 and Pauline Vaillancourt Rosenau, PhD3
(1)University of Texas Houston, Houston, TX, (2)Ingenix Consulting, Missouri City, TX, (3)University of Texas School of Public Health, Houston, TX